{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:07:08Z","timestamp":1761581228400},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,8,28]],"date-time":"2014-08-28T00:00:00Z","timestamp":1409184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s00330-014-3389-1","type":"journal-article","created":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T11:16:41Z","timestamp":1409138201000},"page":"375-379","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Incidence of bowel wall oedema on computed tomography exams and association with diarrhoea in renal cell carcinoma patients treated with sunitinib"],"prefix":"10.1007","volume":"25","author":[{"given":"Liesbeth","family":"Cornelissen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Claus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Wolter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herlinde","family":"Dumez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"De Keyzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyne","family":"Lerut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik","family":"Van Poppel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Beuselinck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,28]]},"reference":[{"key":"3389_CR1","doi-asserted-by":"crossref","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 74\u2013108","DOI":"10.3322\/canjclin.55.2.74"},{"key":"3389_CR2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","volume":"56","author":"A Jemal","year":"2006","unstructured":"Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106\u2013130","journal-title":"CA Cancer J Clin"},{"key":"3389_CR3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00345-004-0466-0","volume":"23","author":"JS Lam","year":"2005","unstructured":"Lam JS, Leppert JT, Belldegrun AS, Figlin R (2005) Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 23:202\u2013212","journal-title":"World J Urol"},{"key":"3389_CR4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115\u2013124","journal-title":"N Engl J Med"},{"key":"3389_CR5","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584\u20133590","journal-title":"J Clin Oncol"},{"key":"3389_CR6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1634\/theoncologist.12-1-107","volume":"12","author":"EP Rock","year":"2007","unstructured":"Rock EP, Goodman V, Jiang JX et al (2007) Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12:107\u2013113","journal-title":"Oncologist"},{"key":"3389_CR7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/02841860903287205","volume":"49","author":"P Wolter","year":"2010","unstructured":"Wolter P, Sch\u00f6ffski P (2010) Targeted therapies in the treatment of GIST: adverse events and maximising the benefits of sunitinib through proactive therapy management. Acta Oncol 49:13\u201323","journal-title":"Acta Oncol"},{"key":"3389_CR8","first-page":"51","volume":"8","author":"A Schwandt","year":"2009","unstructured":"Schwandt A, Wood LS, Rini B, Dreicer R (2009) Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Oncol Targets Ther 8:51\u201361","journal-title":"Oncol Targets Ther"},{"key":"3389_CR9","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1535-7163.MCT-10-1124","volume":"10","author":"G Aparicio-Gallego","year":"2011","unstructured":"Aparicio-Gallego G, Blanco M, Figueroa A et al (2011) New insights into molecular mechanisms of sunitinib-associated side effects. Mol Cancer Ther 10:2215\u20132223","journal-title":"Mol Cancer Ther"},{"key":"3389_CR10","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2214\/ajr.176.5.1761105","volume":"176","author":"M Macari","year":"2001","unstructured":"Macari M, Balthazar EJ (2001) CT of bowel wall thickening: significance and pitfalls of interpretation. AJR Am J Roentgenol 176:1105\u20131116","journal-title":"AJR Am J Roentgenol"},{"key":"3389_CR11","doi-asserted-by":"crossref","first-page":"567486","DOI":"10.1155\/2009\/567486","volume":"2009","author":"A Harandi","year":"2009","unstructured":"Harandi A, Zaidi AS, Stocker AM, Laber DA (2009) Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol 2009:567486","journal-title":"J Oncol"},{"key":"3389_CR12","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1634\/theoncologist.12-12-1443","volume":"12","author":"C Widakowich","year":"2007","unstructured":"Widakowich C, de Castro G Jr, de Azambuja E, Dinh P, Awada A (2007) Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 12:1443\u20131455","journal-title":"Oncologist"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-014-3389-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00330-014-3389-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-014-3389-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T08:02:16Z","timestamp":1559030536000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00330-014-3389-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,28]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["3389"],"URL":"https:\/\/doi.org\/10.1007\/s00330-014-3389-1","relation":{},"ISSN":["0938-7994","1432-1084"],"issn-type":[{"value":"0938-7994","type":"print"},{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,28]]}}}